Abridge announced a collaboration with NVIDIA to scale its artificial intelligence-powered clinical documentation system. Abridge Inc. intends to utilize NVIDIA’s resources, foundation models and expertise to deploy its AI systems at a larger scale.
“We are thrilled to work with NVIDIA to elevate our research efforts,” Zachary Lipton, Abridge chief technology and scientific officer, said in a prepared statement. “The collaboration will help us redefine the possibilities for clinically specialized foundation models, advance medical speech and language technology and innovate in the space of responsible AI.”
Abridge, headquartered in Pittsburgh, utilizes a system of multiple AI technologies to record, transcribe, document and organize conversations between health care providers and patients.
In addition to the partnership, the company received an undisclosed investment from NVentures, NVIDIA’s venture capital firm.
“Generative AI is transforming nearly every aspect of health care,” Mohamed Siddeek, head of NVentures, said in a prepared statement. “Abridge is tapping NVIDIA technologies to help further its foundational research efforts, pioneer and scale methods to advance state-of-the-art AI systems and responsibly deploy these in health care settings.”
Abridge, which was first founded in 2018, has seen significant investments and growth in recent months. In late February the company raised $150 million in what was one of the largest funding rounds in history for health care AI. This funding came just four months after a $30 million Series B funding round.
NVIDIA (NASDAQ: NVDA) has also seen tremendous growth in recent months. Originally a company developing graphics processing units for video editing, 3D rendering and PC gaming, the company has pivoted to selling processors for AI. As the AI market has boomed, NVIDIA has grown to be the third-largest company in the world by market cap, next to only Microsoft and Apple. In addition to selling processors, NVIDIA owns a platform of AI softwares, which Abridge utilizes.
